Abstract:Tumorogenesis is characterized by the unregulated proliferation of cells, which is the consequence of dysregulated cell division mechanisms. To ensure the rapid multiplication and invasion, tumor tend to create unique tumor microenvironment (TME) benefiting its own progression. As abnormal component in the body, figuring out how to escape from the supervision and attack of immune system is the key of tumor survival. Angiogenesis, which is mainly triggered by the stimulation of vascular endothelial growth factor (VEGF), is one of its solutions. Characterized by hypoxia, most type of tumor cells significantly upregulate VEGF, which stimulates active construction of tumor neovascularization. [1][2][3] However, the newly-formed tumor blood vessels show series of abnormalities, including increased luminal resistance, increased endothelial permeability and limited blood flow caused by defects in structure. [4] The features above are beneficial to the tumor growth and metastasis, as well as immune evasion, inducing resistance to immunotherapy. It was reported that anti-angiogenesis therapy has been seen as a promising strategy to enhance tumor immune response, which contributes to improve immunosuppressive TME and helps with anti-tumor effects by immune system. [5][6][7] The relation between angiogenesis and immune response was revealed in gene and transcriptomic level. Kurmyshkina et al. focused on the difference of transcriptomic landscapes between early-stage invasive cervical carcinoma (CeCa) and cervical intraepithelial neoplastic lesions (CIN). The authors found that innate immune pathways in early-stage CeCa were significantly upregulated in response to the infection of human papillomavirus, compared with CIN as precursor lesions. The tumors with active immune infiltration showed a more differentiated phenotype, while the ones with increased expression of genes associated with angiogenesis were related to exacerbation of de-differentiation and epithelial-to-mesenchymal transition. As reported, anti-angiogenesis therapy was expected to improve immune evasion and enhance immune infiltration. Shafqat et al. summarized previous studies which focused on tumor angiogenesis and coagulation exert suppressive effects on anti-tumor immune response. Both of them mediates the impacts above through specific mechanisms ultimately leading to the reprogramming of TME. Whether the usage of anti-angiogenic therapies to achieve vascular normalization and ACEi/ARBs to achieve stromal normalization targeting angiogenesis, or anticoagulants targeting coagulation, showed similar result of limit tumor progression and transform TME to favor immune response against tumors. Also, they both demonstrated the efficacy of enhance immunotherapy while combining with ICIs, despite the heterogeneity of tumor types still needs to be considered in the conjunction. It is natural to associate angiogenesis with prognosis since its influence on tumor invasion and progression. Li et al. developed an advanced machine learning model to evaluate the prognosis and therapy response of breast cancer based on several genes related to vascular mimicry (VM), the performance of which continuously exceeds that of traditional ones. The tumor group received higher VM scores than the normal group. The high-risk group showed higher level of tumor mutation burden (TMB) and higher mutation rate of tumor suppressor genes, and higher level of immune escape suggesting poor response to immunotherapy at the same time. Meanwhile, the low-risk group appeared more favorable response to immune checkpoint blockage. Eventually, the authors identified several promising chemotherapy drugs to which was VM related genes sensitive.To summarize, the studies above introduce some latest advances in the roles of angiogenesis and immune response in TME of solid tumors, and hopefully contribute to the further explorations of immunotherapy enhancer. We would like to acknowledge the invaluable support of all authors, reviewers and the editor team during the topic preparation process. We are looking forward to significant breakthroughs in the approach of sensitizing immunotherapy through anti-angiogenesis agents to emerge soon.

An Interleukin-17–Mediated Paracrine Network Promotes Tumor Resistance to Anti-Angiogenic Therapy

Interleukin-22 promotes tumor angiogenesis

“Γδt Cell-IL17A-Neutrophil” Axis Drives Immunosuppression and Confers Breast Cancer Resistance to High-Dose Anti-VEGFR2 Therapy

'Γδtcells-Il-17a-neutrophils' Axis Drive Immunosuppression and Confer VEGFR2-TKI Refractoriness to Breast Cancer Therapy

Tumor Resistance to Anti-Vegf Therapy Through Up-Regulation of Vegf-C Expression

OA11.07 Combining Anti-Angiogenesis and Immunotherapy Enhances Antitumor Effect by Promoting Immune Response in Lung Cancer

Profiling Analysis of Histone Modifications and Gene Expression in Lewis Lung Carcinoma Murine Cells Resistant to Anti-VEGF Treatment

Immune-Mediated and Hypoxia-Regulated Programs: Accomplices in Resistance to Anti-angiogenic Therapies

Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy

Abstract 175: Tumor-associated monocytes and neutrophils: Targets for immunotherapy

Il-17 is Associated with Poor Prognosis and Promotes Angiogenesis Via Stimulating Vegf Production of Cancer Cells in Colorectal Carcinoma

Intratumoral Delivery of IL-21 Overcomes Anti-Her2/Neu Resistance through Shifting Tumor-Associated Macrophages from M2 to M1 Phenotype

Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade

Interleukin-17-Producing Neutrophils Link Inflammatory Stimuli to Disease Progression by Promoting Angiogenesis in Gastric Cancer

Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression

Abstract 3819: Amphiregulin in Damaged Tumor Microenvironment Potentiates Therapeutic Resistance and Enables PD-L1-mediated Immunosuppression

New Insights into Antiangiogenic Therapy Resistance in Cancer: Mechanisms and Therapeutic Aspects

Editorial: Community series in the role of angiogenesis and immune response in tumor microenvironment of solid tumor, volume III

IL-17A Promotes Tumor Growth Through Enhancing Tumor Angiogenesis and Invasiveness

PDGF-CC Underlies Resistance to VEGF-A Inhibition and Combinatorial Targeting of Both Suppresses Pathological Angiogenesis More Efficiently

IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer